100% found this document useful (1 vote)
225 views39 pages

Dissolution Method Validation Overview

The document discusses validation of dissolution testing methods. It states that an ideal dissolution test should provide information on batch-to-batch consistency, distinguish between different formulations, and correlate to in vivo absorption. The key areas of method validation discussed include selection of apparatus, medium, sampling methods, and establishing linearity, accuracy, precision and robustness of the analytical method.

Uploaded by

Md. Jubair
Copyright
© All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PPT, PDF, TXT or read online on Scribd
100% found this document useful (1 vote)
225 views39 pages

Dissolution Method Validation Overview

The document discusses validation of dissolution testing methods. It states that an ideal dissolution test should provide information on batch-to-batch consistency, distinguish between different formulations, and correlate to in vivo absorption. The key areas of method validation discussed include selection of apparatus, medium, sampling methods, and establishing linearity, accuracy, precision and robustness of the analytical method.

Uploaded by

Md. Jubair
Copyright
© All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PPT, PDF, TXT or read online on Scribd

DISSOLUTION

METHOD
VALIDATION

MOKARAM HOSSAIN Nov 2, 2023 1


 An ideal dissolution test should deliver information in three
key areas:
 First, the dissolution test should be able to detect changes in
the physicochemical properties of the drug product from the
effect of these changes on the rate or amount of the drug
substance released. Such information is useful for the purpose
of establishing batch-to-batch production consistency for
quality control.

MOKARAM HOSSAIN Nov 2, 2023 2


 Second, dissolution testing should be able to distinguish drug
products that have been manufactured using different
processes and/or formulations during the development phase.

MOKARAM HOSSAIN Nov 2, 2023 3


 Finally, when in vitro–in vivo correlation is established,
dissolution should also reflect release and absorption rates in
humans.
 However, not all drug molecules are able to fulfill all three
functions in a dissolution test.

MOKARAM HOSSAIN Nov 2, 2023 4


 a definite volume (usually 500 to 1000 mL) of the dissolution
medium is introduced into a vessel and the temperature is
maintained at 37 ± 0.5◦C.
 The testing assembly (i.e., basket or paddle) is fitted to the
shaft, and the apparatus is adjusted to rotate at a specified rate.

MOKARAM HOSSAIN Nov 2, 2023 5


 The testing assembly is fixed to the shaft following the
compendial requirements for each relative position.
 During operation of the dissolution apparatus, the vessels
should be covered appropriately to prevent evaporation of the
dissolution medium.

MOKARAM HOSSAIN Nov 2, 2023 6


 When the basket apparatus is used, the sample is placed in the
dry basket; the basket fitted to the coupling disk and lowered
to the position specified, and rotation is started immediately.
 When the paddle apparatus is used, the sample is allowed to
sink to the bottom of the vessel, and rotation of the paddle
started immediately at the speed specified.

MOKARAM HOSSAIN Nov 2, 2023 7


 If use of the sinker is required, the sample is placed in the
sinker and allowed to sink to the bottom of the vessel.
 The samples are collected at the appropriate time, filtered by a
suitable method, and
 the filtrate used as the sample solution.

MOKARAM HOSSAIN Nov 2, 2023 8


 The drug substance(s) in the sample solution
is assayed, and the quantity dissolved at the
specified time is expressed as a percentage
of the labeled amount.

MOKARAM HOSSAIN Nov 2, 2023 9


 The time required for the capsule shell or tablet coating to
start breaking apart will provide an indication of possible
issues with the shell or coating that would retard the release of
the formulation (e.g., gelatin cross-linking).

MOKARAM HOSSAIN Nov 2, 2023 10


 The time required for complete disintegration will provide an
indication of possible issues with the dosage unit that could
affect the release of active ingredient (e.g., overcompression
of capsule powders or tablet cores).
 Behavior of the capsule within a specific sinker device (e.g.,
capsules being stuck to the basket mesh).

MOKARAM HOSSAIN Nov 2, 2023 11


 The effectiveness of the mixing within the vessel. Coning (the
formation of a mound of insoluble excipient particles on the
bottom of the vessel) may indicate the need for a higher
rotation speed or the use of different apparatus (e.g., baskets
instead of paddles).

MOKARAM HOSSAIN Nov 2, 2023 12


 The suitability of the media degassing method. The formation
of bubbles during the dissolution process can affect the rate of
release of the active ingredient.

MOKARAM HOSSAIN Nov 2, 2023 13


 Apparatus
 Dissolution Medium
 Rotational Speed
 Sample Collection
 Effect of Non-USP Adaptation
 Cleaning Validation

MOKARAM HOSSAIN Nov 2, 2023 14


 The nature of the dosage form will determine the type of
dissolution apparatus that will be used for method
development and validation.
 The following questions must be asked when selecting the
dissolution apparatus:
 Is it a capsule?
 Will a sinker be required?

MOKARAM HOSSAIN Nov 2, 2023 15


 How stable is the drug substance after dissolution in the
medium?
 Is the formulation an immediate release or an extended release
formulation?
 Is this a transdermal patch?

MOKARAM HOSSAIN Nov 2, 2023 16


 USP Dissolution Apparatus 1 (basket) and 2 (paddle) are
commonly used for immediate-release formulations.
 USP Apparatus 3 (reciprocating cylinders) is the system of
choice for testing extended-release products or a dosage form
that requires release profiling at multiple pH levels and time
points.

MOKARAM HOSSAIN Nov 2, 2023 17


 Low-dose products may require the use of flow-through
analysis or other low-volume test techniques (noncompendial
100- or 200-mL dissolution vessels).
 Once the apparatus is selected and has been shown to be
suitable during method development, no further evaluation of
another apparatus is required during validation.

MOKARAM HOSSAIN Nov 2, 2023 18


 The dissolution medium that is chosen for method
development and validation will depend on a variety of factors
that include:
 The solubility of the drug molecule
 The nature of the dosage form
 The chemical structure of the drug molecule

MOKARAM HOSSAIN Nov 2, 2023 19


 A speed of 100 rpm is commonly used with the basket
apparatus and a speed of 50 rpm is used with paddles.
 The compendial limit for variations in rotational speed is
±4%, but a wider variation (e.g., ±10%) may be considered in
testing the robustness of the method.

MOKARAM HOSSAIN Nov 2, 2023 20


 The two aspects of sample collection that need to be
considered during the development and validation of sample
preparation are
 (1) the withdrawal of the sample aliquot from the dissolution
vessel and
 (2) the clarification (filtration) of the sample aliquot.

MOKARAM HOSSAIN Nov 2, 2023 21


 Filters are required for dissolution sample collection. It is
necessary to filter out the excipents that may cause
interference in sample analysis. Appropriate recovery studies
should be performed and documented. Any observed bias
should be addressed. Filtration must be performed when the
sample aliquots are withdrawn, not at a later time.

MOKARAM HOSSAIN Nov 2, 2023 22


 The development and validation of the dissolution test for new
formulations will often probe into the use of
nonpharmacopoeia adaptations (e.g., peak vessel and unique
sinker configurations). The suitability of these adaptations
must be assessed during method development or validation.

MOKARAM HOSSAIN Nov 2, 2023 23


 Once the vessels have been cleaned, a “blank” dissolution run
needs to be performed to ensure that the cleaning procedure
for the dissolution vessels is appropriate and will not give rise
to contamination.

MOKARAM HOSSAIN Nov 2, 2023 24


 Linearity
 Accuracy
 Precision: Repeatability
 Precision: Intermediate Precision
 Range
 Robustness for HPLC Analysis
 Robustness for UV–Vis Analysis
 Specificity

MOKARAM HOSSAIN Nov 2, 2023 25


 Neat standard solutions are prepared to cover the nominal
concentration of the sample. ICH Q2B proposes an acceptable
range of ±20%.
 A range of 25 to 125% of nominal concentration is commonly
used for the linearity determination.

MOKARAM HOSSAIN Nov 2, 2023 26


 Visual inspection of a plot of response versus concentration
will show a straight line. The correlation coefficient (r),
residual sum of squares, and y-intercept should be reported.

MOKARAM HOSSAIN Nov 2, 2023 27


 Sample solutions of known concentration (e.g., spiked
placebo) are used for the accuracy determination.
 Experimental work may be organized so that the same stock
solutions are used to prepare both linearity and accuracy
solutions.
 The accuracy solution must be exposed to normal test
conditions (e.g., mixing in a heated dissolution vessel).

MOKARAM HOSSAIN Nov 2, 2023 28


 Determine any bias that is caused by the sampling and
analysis of the solutions.
 If a dissolution profile of the drug product is required,
accuracy determinations at different concentrations of the
required profile will need to be performed (e.g., at 40, 75, and
110% of theoretical release).
 The results are reported as percent theory.

MOKARAM HOSSAIN Nov 2, 2023 29


 The repeatability experiment will be performed using six
dissolution samples that are prepared from the same
dissolution apparatus.

MOKARAM HOSSAIN Nov 2, 2023 30


 Sets of six dissolution samples that are prepared using
different instruments and by different analysts are used to
determine intermediate precision

MOKARAM HOSSAIN Nov 2, 2023 31


 Precision

Normalization of dissolution profile to remove tablet-to-


tablet variation

MOKARAM HOSSAIN Nov 2, 2023 32


 The results of the linearity, accuracy, and precision will help
determine the range for the dissolution test (e.g., 25 to 125%
of nominal for a single-point dissolution and ±20% of the
stated range for a dissolution profile for a modified release
formulation).

MOKARAM HOSSAIN Nov 2, 2023 33


 The investigation of the effect of column, mobile phase,
HPLC solution stability, and wavelength is performed in a
manner similar to the HPLC potency/related substance assay.
 For solution stability, the solution can be analyzed on different
days or analyzed on the same day with both aged and fresh
solutions.

MOKARAM HOSSAIN Nov 2, 2023 34


 Wavelength accuracy, wavelength repeatability, diluting
solvent (i.e., pH, concentration), solution stability, and bubble
formation by the sipper can be investigated during validation
of the analytical component.

MOKARAM HOSSAIN Nov 2, 2023 35


 For HPLC analysis, resolution of the drug substance from any
potential excipient and system interference peaks should be
demonstrated.
 For a UV–Vis analysis, the absorption of the placebo solution
should not be significant.

MOKARAM HOSSAIN Nov 2, 2023 36


 There are various situations during the life cycle of a
dissolution test that will require revalidation of the method.
These are similar to those described for the potency assay

MOKARAM HOSSAIN Nov 2, 2023 37


THANK YOU

MOKARAM HOSSAIN Nov 2, 2023 38


 Describe the different sample components of a dissolution
apparatus.
 Describe how to validate sample preparation components of a
dissolution apparatus.
 Explain the discriminating dissolution method.

MOKARAM HOSSAIN Nov 2, 2023 39

You might also like